AEST.MED.INT.HLD.SP.ADR/3 (F:3FMA) — Stock Price
AEST.MED.INT.HLD.SP.ADR/3 (F:3FMA) is currently trading at €0.06 EUR, up 0.87% today. Over the past 52 weeks, shares have ranged between €0.01 and €0.30. This page tracks AEST.MED.INT.HLD.SP.ADR/3's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see 3FMA cash generation efficiency.
AEST.MED.INT.HLD.SP.ADR/3 (3FMA) Stock Price Chart — Daily History & Trading Volume
The chart below tracks AEST.MED.INT.HLD.SP.ADR/3's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
AEST.MED.INT.HLD.SP.ADR/3 Income Statement — Revenue, Profit & Earnings by Year
AEST.MED.INT.HLD.SP.ADR/3's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €722.86 Million | €755.67 Million | €682.59 Million | €670.09 Million | €645.59 Million |
| Cost of Revenue | €388.61 Million | €417.88 Million | €360.54 Million | €314.50 Million | €376.09 Million |
| Gross Profit | €334.25 Million | €337.79 Million | €322.05 Million | €355.59 Million | €269.50 Million |
| Research & Development | — | — | — | — | — |
| SG&A | €329.01 Million | €341.83 Million | €370.86 Million | €376.85 Million | €611.65 Million |
| Total Operating Expenses | €717.62 Million | €759.71 Million | €731.40 Million | €691.36 Million | €987.75 Million |
| Operating Income | €5.24 Million | €-4.04 Million | €-48.81 Million | €-21.27 Million | €-342.15 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €8.75 Million | €8.72 Million | €14.47 Million | €21.64 Million | €27.23 Million |
| Income Before Tax | €-24.72 Million | €-1.35 Million | €-55.06 Million | €-94.17 Million | €-681.31 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €-53.35 Million | €-19.95 Million | €-37.43 Million | €-76.25 Million | €-586.62 Million |
AEST.MED.INT.HLD.SP.ADR/3 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes AEST.MED.INT.HLD.SP.ADR/3's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €510.89 Million | €486.22 Million | €560.66 Million | €546.37 Million | €576.94 Million |
| Total Current Assets | €134.40 Million | €88.08 Million | €111.57 Million | €77.60 Million | €113.71 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | €6.40 Million | €8.79 Million | €9.84 Million | €6.19 Million | €7.77 Million |
| Inventory | €18.80 Million | €14.91 Million | €15.58 Million | €27.85 Million | €30.57 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | €29.28 Million | €33.00 Million | €33.00 Million | €33.00 Million | €33.17 Million |
| Total Liabilities | €554.12 Million | €476.88 Million | €527.03 Million | €672.25 Million | €763.36 Million |
| Total Current Liabilities | €428.55 Million | €402.04 Million | €411.38 Million | €543.84 Million | €541.66 Million |
| Long-term Debt | €15.17 Million | €13.72 Million | €31.41 Million | €29.11 Million | €115.67 Million |
| Net Debt | €83.99 Million | €43.10 Million | €62.51 Million | €254.28 Million | €232.59 Million |
| Total Stockholder Equity | €-20.60 Million | €30.46 Million | €48.89 Million | €-113.66 Million | €-156.67 Million |
| Retained Earnings | €-1.25 Billion | €-1.20 Billion | €-1.18 Billion | €-1.14 Billion | €-1.06 Billion |
AEST.MED.INT.HLD.SP.ADR/3 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how AEST.MED.INT.HLD.SP.ADR/3 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-12.23 Million | €79.67 Million | €74.29 Million | €-75.13 Million | €51.09 Million |
| Capital Expenditures | €6.98 Million | €30.79 Million | €55.46 Million | €1.68 Million | €33.44 Million |
| Free Cash Flow | €-19.20 Million | €48.88 Million | €18.83 Million | €-76.80 Million | €17.65 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | €29.93 Million | €-68.55 Million | €29.06 Million | €45.55 Million | €-45.23 Million |
| Dividends Paid | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 |
| Stock-Based Compensation | €0.00 | €0.00 | €7.51 Million | €27.53 Million | €35.46 Million |
| Depreciation | €58.89 Million | €65.96 Million | €65.90 Million | €61.49 Million | €99.14 Million |
| Change in Cash | €17.42 Million | €-19.20 Million | €51.10 Million | €-26.46 Million | €-5.67 Million |
AEST.MED.INT.HLD.SP.ADR/3 Earnings History — EPS Actual vs. Analyst Estimates
Track AEST.MED.INT.HLD.SP.ADR/3's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Nov 04, 2024 | — | — | — |
| Dec 31, 2020 | -0.20 | 0.10 | -300.00% |
| Sep 30, 2020 | 0.02 | 0.26 | -92.31% |
| Jun 30, 2020 | -0.21 | 0.07 | -400.00% |
| Mar 31, 2020 | -0.39 | 0.01 | -4000.00% |